Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 19 of 19 entries
View as:

Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

Phase: N/A Priority: Normal
NCT ID: NCT00878111 Org: User:
Start: 04/30/09 End: 02/28/17 Due: 02/28/18

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00483509 Org: User:
Start: 02/14/07 End: 05/17/11 Due: 05/17/12

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT00484211 Org: User:
Start: 12/31/06 End: 04/30/13 Due: 04/30/14

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00423124 Org: User:
Start: 07/31/02 End: 11/30/13 Due: 11/30/14

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01358071 Org: User:
Start: 06/30/11 End: 12/31/16 Due: 12/31/17

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00419328 Org: User:
Start: 03/31/05 End: 09/30/07 Due: 09/30/08

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00484432 Org: User:
Start: 11/30/08 End: 06/30/16 Due: 06/30/17

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00675012 Org: User:
Start: 12/31/07 End: 05/31/13 Due: 05/31/14

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

Phase: N/A Priority: Normal
NCT ID: NCT00483080 Org: User:
Start: 12/31/06 End: 04/30/13 Due: 04/30/14

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Phase: N/A Priority: Normal
NCT ID: NCT03804866 Org: User:
Start: 03/31/13 End: 12/31/16 Due: 12/31/17

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT00484276 Org: User:
Start: 05/31/07 End: 03/31/13 Due: 03/31/14

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00914628 Org: User:
Start: 04/12/10 End: 11/30/19 Due: 11/30/20

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Phase: N/A Priority: Normal
NCT ID: NCT01098266 Org: User:
Start: 04/12/10 End: 12/31/17 Due: 12/31/18

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00994097 Org: User:
Start: 07/31/09 End: 03/31/17 Due: 03/31/18

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04097301 Org: User:
Start: 08/27/19 End: 06/18/21 Due: 06/18/22

Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT00483093 Org: User:
Start: 07/31/07 End: 04/30/13 Due: 04/30/14

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

Phase: N/A Priority: Normal
NCT ID: NCT01358084 Org: User:
Start: 03/31/11 End: 12/05/18 Due: 12/05/19

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

Phase: N/A Priority: Normal
NCT ID: NCT00484341 Org: User:
Start: 10/31/10 End: 05/31/16 Due: 05/31/17

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00305084 Org: User:
Start: 02/28/06 End: 05/08/07 Due: 05/08/08